27,808 Danaher Corporation $DHR Shares Purchased by Smithbridge Asset Management Inc. DE

Smithbridge Asset Management Inc. DE boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 240.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 39,387 shares of the conglomerate’s stock after buying an additional 27,808 shares during the period. Danaher makes up approximately 1.2% of Smithbridge Asset Management Inc. DE’s holdings, making the stock its 27th largest holding. Smithbridge Asset Management Inc. DE’s holdings in Danaher were worth $8,726,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of DHR. BlackRock Inc. bought a new position in shares of Danaher in the 2nd quarter valued at $10,492,520,000. Jupiter Topco LLC acquired a new position in shares of Danaher during the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new position in shares of Danaher during the 2nd quarter worth $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher during the 2nd quarter worth $993,846,000. Finally, Legal & General Group Plc bought a new stake in shares of Danaher during the 2nd quarter worth $801,056,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 2.0%

Shares of NYSE DHR opened at $224.45 on Tuesday. The firm has a 50 day moving average price of $214.35 and a two-hundred day moving average price of $196.30. The stock has a market cap of $157.78 billion, a P/E ratio of 28.21, a price-to-earnings-growth ratio of 2.88 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 earnings per share. As a group, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Analysts Set New Price Targets

DHR has been the topic of several research analyst reports. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Sunday. Royal Bank Of Canada boosted their target price on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. The Goldman Sachs Group increased their target price on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, Morgan Stanley raised their price target on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.